CURED Co., Ltd announced that it will issue 88,000 common shares at ¥6,800 per share for gross proceeds of ¥598,400,000 on February 27, 2019. The transaction will include participation from existing investor Immuno-Biological Laboratories Co., Ltd. Post the closing, the investor stake will increase from 5.67% to 23.79% and the number of shares held will increase from 21,000 to 109,000 in the company. The shares will be issued through a third party allotment method. The transaction is expected to close on March 29, 2019. The transaction has been approved by the board of directors of the investor.